p 29

16-Oxolyclanitin-29-yl p-coumarate 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN5971，CAS号为 140701-70-8。

CGP 29030A 是一种新的哌嗪衍生物，具有镇痛活性，对潜在的痛觉背角神经元有显著的抑制作用，可用于研究疼痛性疾病。

SMAP 29是一种抗微生物肽，同时也是绵羊防御素前体肽的C末端切割产物。在低盐和高盐条件下，对P. aeruginosa菌株PAO1具有杀菌作用，该作用在能量依赖的发光测定中表现出来（EC50s分别为0.05和0.06 µM）。它还能够以浓度依赖的方式引起绵羊红细胞的溶血。

Cgp 29287 is a primate-specific renin inhibitor. It also has a prolonged duration of action.

GluR5-subunit containing kainate receptor antagonist

Jtp 2942 is a new thyrotropin-releasing hormone analog.

ASP-2905 是一种有效且选择性的钾通道 Kv12.2抑制剂。ASP2905 (ASP-2905) 可以穿越血脑屏障并具有抗精神病活性。

GP29 is a Type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α.

CP-293019 is a potent, selective antagonist of dopamine D4 receptor.

KRP297 is a PPAR agonist potentially for the treatment of type 2 diabetes and dyslipidemia.

CP-294838 is a bioactive chemical.

SMAP-29 is a broad spectrum antibacterial and antifungal α-helical cathelicidin-derived peptide with strong potential as an antiinfective agent. It effectively permeabilizes bacterial membranes and induces significant alterations in the surface morphology of susceptible microorganisms.

CLP-290 是一种神经特异性 K+-Cl−共转运体 KCC2的口服激活剂，在多种神经和精神疾病方面具有研究潜力。CLP290 能显著降低 STZ 大鼠的血液中 AVP 和血糖水平。

Vilobelimab (CaCP-29) 是一种靶向人补体成分 5a 的人鼠嵌合 IgG 抗体，是一种 C5a 抑制剂，抑制中性粒细胞活化，可用于研究 SARS-CoV-2 感染引起的全身炎症。

Lupeol (Monogynol B) 是一个活跃的五环三萜，具有抗氧化剂、抗肿瘤和抗炎活性。它是一种雄激素受体抑制剂，可研究癌症，特别是雄激素依赖表型和去势抵抗表型的前列腺癌。

ZX-29 是一种选择性ALK 抑制剂，对ALK、ALK L1196M 和ALK G1202R 的IC50分别为 2.1 nM、1.3 nM 和 3.9 nM。它还可诱导保护性自噬并具有抗肿瘤作用。它通过诱导内质网应激来诱导细胞凋亡，并克服了由ALK 突变引起的细胞抗性。

Keenamide A, a cytotoxic cyclic hexapeptide, exhibits significant activity towards the P-388, A-549, MEL-20, and HT-29 tumor cell lines, but was inactive against the D6 and W2 Plasmodium falciparum malarial clones.

Lys05 是一种有效的水溶性溶酶体自噬抑制剂，具有抗肿瘤活性。在 MTT 试验中，对1205Lu、c8161、LN229 和 HT-29细胞系的IC50值分别为3.6、3.8、6 和7.9 μM。

FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC50=1 nM) and good selectivity over other isoforms (IC50s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML[1].

N-(2-Azidoethyl)betulonamide is a pentacyclic triterpenoid, a derivative of betulonic acid , and an intermediate in the synthesis of betulonic acid derivatives within vitrocancer cell cytotoxicity.1 1.Suman, P., Patel, A., Solano, L., et al.Synthesis and cytotoxicity of Baylis-Hillman template derived betulinic acid-triazole conjugatesTetrahedron73(29)4214-4226(2017)

Gliovirin is a fungal metabolite that has been found inT. harzianumand has fungicidal, antimicrobial and anti-inflammatory activities.1It is active against the plant pathogenic fungusP. ultimum(MIC = 60 ng/ml) and the parasiteT. brucei brucei(IC50= 90 ng/ml), but has no effect on the plant pathogenic fungiR. solani,P. omnivorum,T. basicola,R. arrhizus, andV. dahliaeor the bacteriaB. thuringiensis,P. fluorescens, andX. malvacearumwhen used at concentrations up to 1,000 ng/ml.2,3Gliovirin decreases phorbol 12-myristate 13-acetate (TPA)- and ionomycin-induced increased expression of COX-2 (IC50= 1 μM) and protein levels of IL-2 in Jurkat cells (IC50= 5.2 μM).1 1.Rether, J., Serwe, A., Anke, T., et al.Inhibition of inducible tumor necrosis factor-α expression by the fungal epipolythiodiketopiperazine gliovirinBiol. Chem.388(6)627-637(2007) 2.Howell, C.R., and Stipanovic, R.D.Gliovirin, a new antibiotic from Gliocladium virens, and its role in the biological control of Pythium ultimumCan. J. Microbiol.29(3)321-324(1983) 3.Iwatsuki, M., Otoguro, K., Ishiyama, A., et al.In vitro antitrypanosomal activity of 12 low-molecular-weight antibiotics and observations of structure/activity relationshipsJ. Antibiot. (Tokyo)63(10)619-622(2010)

Flumequine-13C3is intended for use as an internal standard for the quantification of flumequine by GC- or LC-MS. Flumequine is a fluoroquinolone antibiotic.1It is active againstS. aureus, S. pyogenes, B. subtilis, E. coli, P. aeruginosa, S. faecalis, andK. pneumoniae(MICs = 1-100 μg ml). Flumequine is also active against field isolates of B. hyodysenteriae (MICs = 6.25-200 μg ml).2It inhibits DNA gyrase, disrupting supercoiling of bacterial DNA to block transcription and replication.3In vivo, flumequine (50 mg kg) increases survival in rat models ofP. vulgaris-induced urinary tract infection andP. mirabilis-induced prostatitis.1Formulations containing flumequine have been used in the treatment of urinary tract infections in veterinary medicine. 1.Rohlfing, S.R., Gerster, J.R., and Kvam, D.C.Bioevaluation of the antibacterial flumequine for urinary tract useAntimicrob. Agents Chemother.10(1)20-24(1976) 2.Aller-Morán, L.M., Martínez-Lobo, F.J., Rubio, P., et al.Evaluation of the in vitro activity of flumequine against field isolates of Brachyspira hyodysenteriaeRes. Vet. Sci.10351-53(2015) 3.Smith, J.T.The mode of action of 4-quinolones and possible mechanisms of resistanceJ. Antimicrob. Chemother.18 (Suppl. D)21-29(1986)

N-p-Tosyl-Gly-Pro-Lys-pNA is a colorimetric substrate for plasmin.1,2,3Plasmin binds and hydrolyzes N-p-tosyl-Gly-Pro-Lys-pNA to releasep-nitroanilide (pNA), which can be quantified by colorimetric detection at 405 nm as a measure of plasmin activity. 1.Jespersen, J., Gram, J., and Astrup, T.The autodigestion of human plasmin follows a bimolecular mode of reaction subject to product inhibitionThromb. Res.41(3)395-404(1986) 2.Kim, S.H., and Choi, N.S.Electrophoretic analysis of protease inhibitors in fibrin zymographyAnal. Biochem.270(1)179-181(1999) 3.Chen, T., and Rael, E.D.Purification of M5, a fibrinolytic proteinase from Crotalus molossus molossus venom that attacks complementInt. J. Biochem. Cell Biol.29(5)789-799(1997)

Pal-KTTKS is a lipidated pentapeptide consisting of a fragment of the type I collagen C-terminal propeptide conjugated to palmitic acid .1 It increases collagen production in human corneal and dermal fibroblasts when used at concentrations of 0.002, 0.004, and 0.008 wt%.2 Following topical administration, pal-KTTKS (50 μg/cm2) is found in the stratum corneum, epidermis, and dermis of isolated hairless mouse skin.1 It can self-assemble into flat tapes and extended fibrillar structures.3 Pal-KTTKS has been detected in anti-wrinkle creams.4 |1. Choi, Y.L., Park, E.J., Kim, E., et al. Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol. Ther. (Seoul) 22(4), 321-327 (2014).|2. Jones, R.R., Castelletto, V., Connon, C.J., et al. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol. Pharm. 10(3), 1063-1069 (2013).|3. Castelletto, V., Hamley, I.W., Whitehouse, C., et al. Self-assembly of palmitoyl lipopeptides used in skin care products. Langmuir 29(29), 9149-9155 (2013).|4. Chirita, R.-I., Chaimbbault, P., Archambault, J.-C., et al. Development of a LC-MS/MS method to monitor palmitoyl peptides content in anti-wrinkle cosmetics. Anal. Chim. Acta 641(1-2), 95-100 (2009).